At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 226 enrolled
Drug / intervention
Rosiglitazone +1 moredrug
Likely dose
Rosiglitazone 8mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A 52 Week Randomized, Double-Blind, Multicenter, Mechanistic Study With a 24 Week Open-Label Follow-Up to Evaluate the Effect of AVANDIA TM on Bone in Postmenopausal Women With Type 2 Diabetes Mellitus
In Brief
A Phase 4 clinical trial evaluating Rosiglitazone and Metformin for Diabetes Mellitus, Type 2. Completed, enrolled 226 participants across 42 sites in 8 countries.
Detailed Summary
The purpose of this study is to determine the effects of rosiglitazone on the bone in postmenopausal women with type 2 diabetes mellitus
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes Mellitus, Type 2
CountriesArgentina, Canada, Estonia, Mexico, Pakistan, Philippines, Spain, United States
Collaborators--
Timeline
Phase 4CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartApr 2008
First PostedMay 2008
Primary CompletionSep 2010
TodayJul 2026
First PostedMay 19, 2008
Enrollment StartApr 21, 2008
Primary CompletionSep 16, 2010
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 18.1 years ago
Interventions
Rosiglitazonedrug
up to 8mg/day
Metformindrug
up to 2000mg/day